相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer.
DJ Slamon et al.
CANCER RESEARCH (2010)
Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer
Hamouda Boussen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
Sara K. Taylor et al.
ONCOLOGIST (2010)
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Herbert I. Hurwitz et al.
CLINICAL CANCER RESEARCH (2009)
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+cohort in EGF103009, a phase II study
Bella Kaufman et al.
LANCET ONCOLOGY (2009)
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The medical treatment of inflammatory breast cancer
Shaheenah Dawood et al.
SEMINARS IN ONCOLOGY (2008)
Defining the molecular biology of inflammatory breast cancer
Emmanuelle Charafe-Lauffret et al.
SEMINARS IN ONCOLOGY (2008)
Inflammatory breast cancer: current understanding
Luc Y. Dirix et al.
CURRENT OPINION IN ONCOLOGY (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
KW Hance et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
High incidence of HER-2 positivity in inflammatory breast cancer
M Parton et al.
BREAST (2004)
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
GE Konecny et al.
CLINICAL CANCER RESEARCH (2004)
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
E Charafe-Jaufrret et al.
JOURNAL OF PATHOLOGY (2004)
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification
I Van der Auwera et al.
CLINICAL CANCER RESEARCH (2004)
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer
CG Kleer et al.
BREAST CANCER RESEARCH (2004)
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression
CG Colpaert et al.
BRITISH JOURNAL OF CANCER (2003)
Update on the management of inflammatory breast cancer
M Cristofanilli et al.
ONCOLOGIST (2003)
分享论文
